Lenalidomide - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (4)Transporters (1)

Targets (4)Transporters (1)Biointeractions (4)

Identification

Name

Lenalidomide

Accession Number

DB00480 (APRD01303)

Type

Small Molecule

Groups

Approved

Description

Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline

3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione

CC-5013

CDC 501

IMid-1

IMiD3

Revlimid

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Revlimid	Capsule	5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	15 mg/1	Oral	Celgene	2006-06-29	Not applicable	US
Revlimid	Capsule	20 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	2.5 mg	Oral	Celgene	2016-12-20	Not applicable	Canada
Revlimid	Capsule	25 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	5 mg	Oral	Celgene	2008-02-19	Not applicable	Canada
Revlimid	Capsule	10 mg/1	Oral	Celgene	2005-12-27	Not applicable	US
Revlimid	Capsule	2.5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	25 mg	Oral	Celgene	2008-10-10	Not applicable	Canada
Revlimid	Capsule	10 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	20 mg/1	Oral	Celgene	2013-06-06	Not applicable	US
Revlimid	Capsule	2.5 mg/1	Oral	Celgene	2012-04-16	Not applicable	US
Revlimid	Capsule	2.5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	10 mg	Oral	Celgene	2008-02-19	Not applicable	Canada
Revlimid	Capsule	5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	20 mg	Oral	Celgene	2015-09-28	Not applicable	Canada
Revlimid	Capsule	15 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU
Revlimid	Capsule	25 mg/1	Oral	Celgene	2006-06-29	Not applicable	US
Revlimid	Capsule	5 mg/1	Oral	Celgene	2005-12-27	Not applicable	US
Revlimid	Capsule	15 mg	Oral	Celgene	2008-10-10	Not applicable	Canada
Revlimid	Capsule	7.5 mg	Oral	Celgene Europe Limited	2007-06-14	Not applicable	EU

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Ladevina	Not Available
Lenangio	Not Available

Brand mixtures

Not Available

Categories

UNII

F0P408N6V4

CAS number

191732-72-6

Weight

Average: 259.2606
Monoisotopic: 259.095691297

Chemical Formula

C₁₃H₁₃N₃O₃

InChI Key

GOTYRUGSSMKFNF-UHFFFAOYSA-N

InChI

InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

IUPAC Name

3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

SMILES

NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O

Pharmacology

Indication

Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Structured Indications

Pharmacodynamics

Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. Lenalidomide does not prolong the QTc interval.

Mechanism of action

The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Protein cereblon	Protein	yes	inhibitor	Human	Q96SW2	details
Tumor necrosis factor ligand superfamily member 11	Protein	yes	inhibitor	Human	O14788	details
Cadherin-5	Protein	unknown	antagonist	Human	P33151	details
Prostaglandin G/H synthase 2	Protein	unknown	negative modulator	Human	P35354	details

Absorption

Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (C_max) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses.

Volume of distribution

Not Available

Protein binding

30% protein bound.

Metabolism

Lenalidomide undergoes limited metabolism. Unchanged lenalidomide is the predominant circulating component in humans. Two identified metabolites are hydroxy-lenalidomide and N-acetyl-lenalidomide; each constitutes less than 5% of parent levels in circulation. The cytochrome P450 enzyme system is not involved with the metabolism of lenalidomide.

Route of elimination

Elimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.

Half life

Healthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours.

Clearance

The renal clearance of lenalidomide exceeds the glomerular filtration rate.

Toxicity

The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Acetaminophen	The serum concentration of Lenalidomide can be increased when it is combined with Acetaminophen.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Lenalidomide.	Approved
Afatinib	The serum concentration of Lenalidomide can be increased when it is combined with Afatinib.	Approved
Albendazole	The serum concentration of Lenalidomide can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Lenalidomide can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Lenalidomide can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Lenalidomide can be increased when it is combined with Alfentanil.	Approved, Illicit
Amantadine	The serum concentration of Lenalidomide can be increased when it is combined with Amantadine.	Approved
Aminohippuric acid	The serum concentration of Lenalidomide can be increased when it is combined with Aminohippuric acid.	Approved
Amiodarone	The serum concentration of Lenalidomide can be decreased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Lenalidomide can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Lenalidomide can be increased when it is combined with Amlodipine.	Approved
Amprenavir	The serum concentration of Lenalidomide can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Lenalidomide can be increased when it is combined with Amsacrine.	Approved
Astemizole	The serum concentration of Lenalidomide can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Lenalidomide can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Lenalidomide can be increased when it is combined with Atenolol.	Approved
Atorvastatin	The serum concentration of Lenalidomide can be increased when it is combined with Atorvastatin.	Approved
Azelastine	The serum concentration of Lenalidomide can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Lenalidomide can be increased when it is combined with Azithromycin.	Approved
Bazedoxifene	Bazedoxifene may increase the thrombogenic activities of Lenalidomide.	Approved, Investigational
BCG vaccine	The therapeutic efficacy of Bcg can be decreased when used in combination with Lenalidomide.	Investigational
Benzocaine	The serum concentration of Lenalidomide can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Lenalidomide can be increased when it is combined with Bepridil.	Approved, Withdrawn
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Lenalidomide.	Approved, Investigational
Biperiden	The serum concentration of Lenalidomide can be increased when it is combined with Biperiden.	Approved
Bosutinib	The serum concentration of Lenalidomide can be increased when it is combined with Bosutinib.	Approved
Bromocriptine	The serum concentration of Lenalidomide can be increased when it is combined with Bromocriptine.	Approved, Investigational
Buprenorphine	The serum concentration of Lenalidomide can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Lenalidomide can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenalidomide.	Approved
Caffeine	The serum concentration of Lenalidomide can be increased when it is combined with Caffeine.	Approved
Canagliflozin	The serum concentration of Lenalidomide can be increased when it is combined with Canagliflozin.	Approved
Candesartan	The serum concentration of Lenalidomide can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Lenalidomide can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Lenalidomide can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carvedilol	The serum concentration of Lenalidomide can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Lenalidomide can be increased when it is combined with Caspofungin.	Approved
Chloroquine	The serum concentration of Lenalidomide can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorotrianisene	Chlorotrianisene may increase the thrombogenic activities of Lenalidomide.	Withdrawn
Chlorpromazine	The serum concentration of Lenalidomide can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Lenalidomide can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Lenalidomide can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The serum concentration of Lenalidomide can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Lenalidomide can be decreased when it is combined with Cholic Acid.	Approved
Cilazapril	The serum concentration of Lenalidomide can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Lenalidomide can be decreased when it is combined with Cimetidine.	Approved
Ciprofloxacin	The serum concentration of Lenalidomide can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Citalopram	The serum concentration of Lenalidomide can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Lenalidomide can be increased when it is combined with Clarithromycin.	Approved
Clofazimine	The serum concentration of Lenalidomide can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Lenalidomide can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clotrimazole	The serum concentration of Lenalidomide can be decreased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Clozapine.	Approved
Cobicistat	The serum concentration of Lenalidomide can be increased when it is combined with Cobicistat.	Approved
Colchicine	The serum concentration of Lenalidomide can be increased when it is combined with Colchicine.	Approved
Colforsin	The serum concentration of Lenalidomide can be increased when it is combined with Colforsin.	Experimental
Conjugated estrogens	Conjugated Equine Estrogens may increase the thrombogenic activities of Lenalidomide.	Approved
Crizotinib	The serum concentration of Lenalidomide can be increased when it is combined with Crizotinib.	Approved
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Lenalidomide.	Approved, Investigational
Cyclosporine	The serum concentration of Lenalidomide can be decreased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Daclatasvir	The serum concentration of Lenalidomide can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Lenalidomide can be increased when it is combined with Dactinomycin.	Approved
Darbepoetin alfa	Darbepoetin alfa may increase the thrombogenic activities of Lenalidomide.	Approved, Investigational
Dasatinib	The serum concentration of Lenalidomide can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Lenalidomide can be decreased when it is combined with Daunorubicin.	Approved
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Lenalidomide.	Approved
Desipramine	The serum concentration of Lenalidomide can be increased when it is combined with Desipramine.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Lenalidomide.	Approved
Desloratadine	The serum concentration of Lenalidomide can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	Dexamethasone may increase the thrombogenic activities of Lenalidomide.	Approved, Investigational, Vet Approved
Dexamethasone	The serum concentration of Lenalidomide can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of Lenalidomide can be increased when it is combined with Dextromethorphan.	Approved
Diclofenac	The serum concentration of Lenalidomide can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dienestrol	Dienestrol may increase the thrombogenic activities of Lenalidomide.	Approved
Diethylstilbestrol	Diethylstilbestrol may increase the thrombogenic activities of Lenalidomide.	Approved
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Lenalidomide.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Lenalidomide.	Approved
Dihydroergotamine	The serum concentration of Lenalidomide can be increased when it is combined with Dihydroergotamine.	Approved
Diltiazem	The serum concentration of Lenalidomide can be increased when it is combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Lenalidomide can be increased when it is combined with Dipyridamole.	Approved
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.	Approved, Investigational
Doxazosin	The serum concentration of Lenalidomide can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Lenalidomide can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Lenalidomide can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Dronabinol	The serum concentration of Lenalidomide can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of Lenalidomide can be increased when it is combined with Dronedarone.	Approved
Elbasvir	The serum concentration of Lenalidomide can be increased when it is combined with Elbasvir.	Approved
Enalapril	The serum concentration of Lenalidomide can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Lenalidomide can be increased when it is combined with Enzalutamide.	Approved
Equol	S Equol may increase the thrombogenic activities of Lenalidomide.	Investigational
Ergonovine	The serum concentration of Lenalidomide can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Lenalidomide can be increased when it is combined with Ergotamine.	Approved
Erythromycin	The serum concentration of Lenalidomide can be decreased when it is combined with Erythromycin.	Approved, Vet Approved
Erythropoietin	Erythropoietin may increase the thrombogenic activities of Lenalidomide.	Approved
Estradiol	Estradiol may increase the thrombogenic activities of Lenalidomide.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Lenalidomide can be increased when it is combined with Estramustine.	Approved
Estriol	Estriol may increase the thrombogenic activities of Lenalidomide.	Approved, Vet Approved
Estrone	Estrone may increase the thrombogenic activities of Lenalidomide.	Approved
Ethinyl Estradiol	Ethinyl Estradiol may increase the thrombogenic activities of Lenalidomide.	Approved
Etoposide	The serum concentration of Lenalidomide can be increased when it is combined with Etoposide.	Approved
Etravirine	The serum concentration of Lenalidomide can be increased when it is combined with Etravirine.	Approved
Felodipine	The serum concentration of Lenalidomide can be increased when it is combined with Felodipine.	Approved, Investigational
Fentanyl	The serum concentration of Lenalidomide can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The serum concentration of Lenalidomide can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Lenalidomide can be increased when it is combined with Fidaxomicin.	Approved
Fingolimod	Lenalidomide may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational
Fluconazole	The serum concentration of Lenalidomide can be increased when it is combined with Fluconazole.	Approved
Fluoxetine	The serum concentration of Lenalidomide can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Lenalidomide can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Lenalidomide can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Lenalidomide can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluvoxamine	The serum concentration of Lenalidomide can be increased when it is combined with Fluvoxamine.	Approved, Investigational
G17DT	The risk or severity of adverse effects can be increased when Lenalidomide is combined with G17DT.	Investigational
Gefitinib	The serum concentration of Lenalidomide can be increased when it is combined with Gefitinib.	Approved, Investigational
Genistein	Genistein may increase the thrombogenic activities of Lenalidomide.	Investigational
Glyburide	The serum concentration of Lenalidomide can be increased when it is combined with Glyburide.	Approved
Gramicidin D	The serum concentration of Lenalidomide can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of Lenalidomide can be increased when it is combined with Grepafloxacin.	Withdrawn
Haloperidol	The serum concentration of Lenalidomide can be increased when it is combined with Haloperidol.	Approved
Hexestrol	Hexestrol may increase the thrombogenic activities of Lenalidomide.	Withdrawn
Hydrocortisone	The serum concentration of Lenalidomide can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Idelalisib	The serum concentration of Lenalidomide can be increased when it is combined with Idelalisib.	Approved
Imatinib	The serum concentration of Lenalidomide can be increased when it is combined with Imatinib.	Approved
Imipramine	The serum concentration of Lenalidomide can be increased when it is combined with Imipramine.	Approved
Indinavir	The serum concentration of Lenalidomide can be decreased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Lenalidomide can be increased when it is combined with Indomethacin.	Approved, Investigational
INGN 201	The risk or severity of adverse effects can be increased when Lenalidomide is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Lenalidomide is combined with INGN 225.	Investigational
Isavuconazonium	The serum concentration of Lenalidomide can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Itraconazole	The serum concentration of Lenalidomide can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Lenalidomide can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Lenalidomide can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ketamine	The serum concentration of Lenalidomide can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketoconazole	The serum concentration of Lenalidomide can be increased when it is combined with Ketoconazole.	Approved, Investigational
Lansoprazole	The serum concentration of Lenalidomide can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Lenalidomide can be increased when it is combined with Lapatinib.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Leflunomide.	Approved, Investigational
Levofloxacin	The serum concentration of Lenalidomide can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levothyroxine	The serum concentration of Lenalidomide can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Lenalidomide can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Liothyronine	The serum concentration of Lenalidomide can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Lenalidomide can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Lenalidomide can be increased when it is combined with Lisinopril.	Approved, Investigational
Lomitapide	The serum concentration of Lenalidomide can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Lenalidomide can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Lenalidomide can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Lenalidomide can be increased when it is combined with Loratadine.	Approved
Losartan	The serum concentration of Lenalidomide can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of Lenalidomide can be increased when it is combined with Lovastatin.	Approved, Investigational
Lumacaftor	The serum concentration of Lenalidomide can be decreased when it is combined with Lumacaftor.	Approved
Maprotiline	The serum concentration of Lenalidomide can be increased when it is combined with Maprotiline.	Approved
Mebendazole	The serum concentration of Lenalidomide can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mefloquine	The serum concentration of Lenalidomide can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Lenalidomide can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meprobamate	The serum concentration of Lenalidomide can be increased when it is combined with Meprobamate.	Approved, Illicit
Mestranol	Mestranol may increase the thrombogenic activities of Lenalidomide.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Lenalidomide.	Withdrawn
Methadone	The serum concentration of Lenalidomide can be increased when it is combined with Methadone.	Approved
Methallenestril	Methallenestril may increase the thrombogenic activities of Lenalidomide.	Experimental
Methoxy polyethylene glycol-epoetin beta	Methoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Lenalidomide.	Approved
Metoprolol	The serum concentration of Lenalidomide can be increased when it is combined with Metoprolol.	Approved, Investigational
Mibefradil	The serum concentration of Lenalidomide can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Lenalidomide can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Lenalidomide can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Lenalidomide can be decreased when it is combined with Mifepristone.	Approved, Investigational
Mitomycin	The serum concentration of Lenalidomide can be increased when it is combined with Mitomycin.	Approved
Mitoxantrone	The serum concentration of Lenalidomide can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Morphine	The serum concentration of Lenalidomide can be increased when it is combined with Morphine.	Approved, Investigational
Naltrexone	The serum concentration of Lenalidomide can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Lenalidomide can be increased when it is combined with Naringenin.	Experimental
Natalizumab	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.	Approved, Investigational
Nefazodone	The serum concentration of Lenalidomide can be decreased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Lenalidomide can be decreased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Lenalidomide can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nicardipine	The serum concentration of Lenalidomide can be increased when it is combined with Nicardipine.	Approved
Nifedipine	The serum concentration of Lenalidomide can be decreased when it is combined with Nifedipine.	Approved
Nilotinib	The serum concentration of Lenalidomide can be increased when it is combined with Nilotinib.	Approved, Investigational
Nisoldipine	The serum concentration of Lenalidomide can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Lenalidomide can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine.	Approved
Norethisterone	The serum concentration of Lenalidomide can be decreased when it is combined with Norethisterone.	Approved
Oleandrin	Anvirzel may decrease the cardiotoxic activities of Lenalidomide.	Experimental
Omeprazole	The serum concentration of Lenalidomide can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ouabain	Ouabain may decrease the cardiotoxic activities of Lenalidomide.	Approved
P-Nitrophenol	The serum concentration of Lenalidomide can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenalidomide.	Approved, Vet Approved
Palmitic Acid	The serum concentration of Lenalidomide can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Lenalidomide can be increased when it is combined with Pantoprazole.	Approved
Paroxetine	The serum concentration of Lenalidomide can be increased when it is combined with Paroxetine.	Approved, Investigational
Perindopril	The serum concentration of Lenalidomide can be increased when it is combined with Perindopril.	Approved
Phenobarbital	The serum concentration of Lenalidomide can be decreased when it is combined with Phenobarbital.	Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.	Approved, Investigational
Pimozide	The serum concentration of Lenalidomide can be increased when it is combined with Pimozide.	Approved
Platelet Activating Factor	The serum concentration of Lenalidomide can be decreased when it is combined with Platelet Activating Factor.	Experimental
Ponatinib	The serum concentration of Lenalidomide can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The serum concentration of Lenalidomide can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pravastatin	The serum concentration of Lenalidomide can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Lenalidomide can be increased when it is combined with Prazosin.	Approved
Prednisone	The serum concentration of Lenalidomide can be increased when it is combined with Prednisone.	Approved, Vet Approved
Probenecid	The serum concentration of Lenalidomide can be increased when it is combined with Probenecid.	Approved
Progesterone	The serum concentration of Lenalidomide can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promestriene	Promestriene may increase the thrombogenic activities of Lenalidomide.	Investigational
Promethazine	The serum concentration of Lenalidomide can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Lenalidomide can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Lenalidomide can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Lenalidomide can be increased when it is combined with Protriptyline.	Approved
Quercetin	The serum concentration of Lenalidomide can be increased when it is combined with Quercetin.	Experimental
Quinacrine	The serum concentration of Lenalidomide can be increased when it is combined with Quinacrine.	Approved
Quinestrol	Quinestrol may increase the thrombogenic activities of Lenalidomide.	Approved
Quinidine	The serum concentration of Lenalidomide can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Lenalidomide can be increased when it is combined with Quinine.	Approved
Ranitidine	The serum concentration of Lenalidomide can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Lenalidomide can be increased when it is combined with Ranolazine.	Approved, Investigational
Reboxetine	The serum concentration of Lenalidomide can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Lenalidomide can be increased when it is combined with Regorafenib.	Approved
Reserpine	The serum concentration of Lenalidomide can be decreased when it is combined with Reserpine.	Approved
Rifampicin	The serum concentration of Lenalidomide can be decreased when it is combined with Rifampicin.	Approved
Rilpivirine	The serum concentration of Lenalidomide can be increased when it is combined with Rilpivirine.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when Lenalidomide is combined with CDX-110.	Investigational
Ritonavir	The serum concentration of Lenalidomide can be decreased when it is combined with Ritonavir.	Approved, Investigational
Roflumilast	Roflumilast may increase the immunosuppressive activities of Lenalidomide.	Approved
Rolapitant	The serum concentration of Lenalidomide can be increased when it is combined with Rolapitant.	Approved
Saquinavir	The serum concentration of Lenalidomide can be decreased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Lenalidomide can be increased when it is combined with Scopolamine.	Approved
Secoisolariciresinol	Secoisolariciresinol may increase the thrombogenic activities of Lenalidomide.	Investigational
Selegiline	The serum concentration of Lenalidomide can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Sertraline	The serum concentration of Lenalidomide can be increased when it is combined with Sertraline.	Approved
Simeprevir	The serum concentration of Lenalidomide can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Lenalidomide can be increased when it is combined with Simvastatin.	Approved
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lenalidomide.	Approved
Sirolimus	The serum concentration of Lenalidomide can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sorafenib	The serum concentration of Lenalidomide can be increased when it is combined with Sorafenib.	Approved, Investigational
Spironolactone	The serum concentration of Lenalidomide can be increased when it is combined with Spironolactone.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Lenalidomide is combined with SRP 299.	Investigational
St. John's Wort	The serum concentration of Lenalidomide can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Lenalidomide can be increased when it is combined with Staurosporine.	Experimental
Streptozocin	The serum concentration of Lenalidomide can be decreased when it is combined with Streptozocin.	Approved
Sulfinpyrazone	The serum concentration of Lenalidomide can be increased when it is combined with Sulfinpyrazone.	Approved
Sumatriptan	The serum concentration of Lenalidomide can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Lenalidomide can be increased when it is combined with Sunitinib.	Approved, Investigational
Synthetic Conjugated Estrogens, A	Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lenalidomide.	Approved
Synthetic Conjugated Estrogens, B	Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide.	Approved
Tacrine	The serum concentration of Lenalidomide can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The risk or severity of adverse effects can be increased when Tacrolimus is combined with Lenalidomide.	Approved, Investigational
Tacrolimus	The serum concentration of Lenalidomide can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Lenalidomide can be decreased when it is combined with Tamoxifen.	Approved
Taurocholic Acid	The serum concentration of Lenalidomide can be increased when it is combined with Taurocholic Acid.	Experimental
Telmisartan	The serum concentration of Lenalidomide can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of Lenalidomide can be increased when it is combined with Temsirolimus.	Approved
Terazosin	The serum concentration of Lenalidomide can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Lenalidomide can be increased when it is combined with Terfenadine.	Withdrawn
Tesmilifene	The serum concentration of Lenalidomide can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Lenalidomide can be increased when it is combined with Testosterone.	Approved, Investigational
Tibolone	Tibolone may increase the thrombogenic activities of Lenalidomide.	Approved
Ticagrelor	The serum concentration of Lenalidomide can be increased when it is combined with Ticagrelor.	Approved
Tofacitinib	Lenalidomide may increase the immunosuppressive activities of Tofacitinib.	Approved, Investigational
Tolvaptan	The serum concentration of Lenalidomide can be increased when it is combined with Tolvaptan.	Approved
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Lenalidomide.	Approved, Investigational
Trazodone	The serum concentration of Lenalidomide can be decreased when it is combined with Trazodone.	Approved, Investigational
Trifluoperazine	The serum concentration of Lenalidomide can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Lenalidomide can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Lenalidomide can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Lenalidomide can be increased when it is combined with Trimipramine.	Approved
Venlafaxine	The serum concentration of Lenalidomide can be increased when it is combined with Venlafaxine.	Approved
Verapamil	The serum concentration of Lenalidomide can be decreased when it is combined with Verapamil.	Approved
Vinblastine	The serum concentration of Lenalidomide can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Lenalidomide can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Lenalidomide can be increased when it is combined with Vinorelbine.	Approved, Investigational
Zimelidine	The serum concentration of Lenalidomide can be increased when it is combined with Zimelidine.	Withdrawn

Food Interactions

When given with a fatty meal, the extent of absorption is reduced.

References

Synthesis Reference

Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Rajasekhar Kadaboina, Veerender Murki, Amarendhar Manda, Venkata Rao Badisa, Naresh Vemula, Rama Seshagiri Rao Pulla, Venu Nalivela, "PREPARATION OF LENALIDOMIDE." U.S. Patent US20110021567, issued January 27, 2011.

US20110021567

General References

List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. [PubMed:15703420 ]
Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. [PubMed:16569772 ]
Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. [PubMed:16344099 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14623
KEGG Drug	D04687
PubChem Compound	216326
PubChem Substance	46505725
ChemSpider	187515
BindingDB	50078323
ChEBI	63791
ChEMBL	CHEMBL848
Therapeutic Targets Database	DAP001255
PharmGKB	PA162363968
Drug Product Database	20185
RxList	http://www.rxlist.com/revlimid-drug.htm
Drugs.com	http://www.drugs.com/cdi/lenalidomide.html
Wikipedia	Lenalidomide

ATC Codes

L04AX04 — Lenalidomide

AHFS Codes

10:00

PDB Entries

Not Available

FDA label

Download (400 KB)

MSDS

Download (225 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Basic Science	Plasma Cell Myeloma	1
0	Terminated	Treatment	Adult T-cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease / Leukemia, Adult T-Cell / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphoma Unspecified / T/Null Cell Systemic Type	1
0	Terminated	Treatment	Multiple Myeloma (MM)	1
0	Unknown Status	Treatment	Myelodysplasia	1
1	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL)	1
1	Active Not Recruiting	Treatment	Acute Myelocytic Leukemia / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukaemias (AML) / Acute Non-Lymphocytic Leukemia	1
1	Active Not Recruiting	Treatment	Adenoidcystic Carcinoma / Neuroendocrine Tumors / Solid Organ Malignancies	1
1	Active Not Recruiting	Treatment	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia	1
1	Active Not Recruiting	Treatment	Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Alkylating Agent-Related Acute Myeloid Leukemia / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Nodal Marginal Zone Lymphoma / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Richter's Syndrome / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1	Active Not Recruiting	Treatment	Advanced Cancers	1
1	Active Not Recruiting	Treatment	Anaplastic Astrocytoma (AA) / Diffuse Intrinsic Pontine Glioma (DIPG) / High Grade Glioma (HGG)	1
1	Active Not Recruiting	Treatment	B Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	1
1	Active Not Recruiting	Treatment	CD20 Positive / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma	1
1	Active Not Recruiting	Treatment	Cancer of the Urethra / Ureteral Cancer / Urethral Cancer / Urethral Neoplasms	1
1	Active Not Recruiting	Treatment	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1	Active Not Recruiting	Treatment	Hodgkins Disease (HD)	1
1	Active Not Recruiting	Treatment	Leukaemia, Acute	1
1	Active Not Recruiting	Treatment	Leukemia Lymphocytic Chronic B-Cell	1
1	Active Not Recruiting	Treatment	Leukemias	1
1	Active Not Recruiting	Treatment	Lymphoma, Hodgkins	1
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Plasma Cell Myeloma	1
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
1	Active Not Recruiting	Treatment	Multiple Myeloma in Relapse	1
1	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Active Not Recruiting	Treatment	Plasma Cell Myeloma	1
1	Active Not Recruiting	Treatment	Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma	1
1	Active Not Recruiting	Treatment	Recurrent Colon Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Rectal Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage IVA Colon Cancer / Stage IVA Colon Cancer AJCC v7 / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Rectal Cancer / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer / Stage IVB Colon Cancer AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Rectal Cancer / Stage IVB Rectal Cancer AJCC v7 / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary	1
1	Active Not Recruiting	Treatment	Recurrent Follicular Lymphoma	1
1	Active Not Recruiting	Treatment	Refractory/Relapsed Indolent Non-Hodgkin Lymphoma	1
1	Active Not Recruiting	Treatment	Relapsed/Refractory B-cell Lymphoma	1
1	Completed	Not Available	Healthy Volunteers	2
1	Completed	Treatment	Acute Myelogenous Leukaemia (AML)	1
1	Completed	Treatment	Acute Myeloid Leukaemias (AML) / Bone Marrow Diseases / Chronic Myelomonocytic Leukemia / Myeldysplastic Syndrome (MDS) / Neutropenias	1
1	Completed	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia	1
1	Completed	Treatment	Adult T-cell lymphomas/leukaemias / Peripheral T-Cell Lymphoma (PTCL)	1
1	Completed	Treatment	Advanced Cancer, Various, NOS	1
1	Completed	Treatment	Advanced Cancers	1
1	Completed	Treatment	Anemias / Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Thrombocytopenias	1
1	Completed	Treatment	Brain and Central Nervous System Tumors	1
1	Completed	Treatment	Childhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma	1
1	Completed	Treatment	Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)	1
1	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemia, B-Cell, Chronic	1
1	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)	1
1	Completed	Treatment	Healthy, Male	1
1	Completed	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell	1
1	Completed	Treatment	Malignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Malignant Melanoma	1
1	Completed	Treatment	Melanoma	1
1	Completed	Treatment	Multiple Myeloma (MM)	11
1	Completed	Treatment	Multiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
1	Completed	Treatment	Myelodysplasia	1
1	Completed	Treatment	Myelodysplastic Syndrome	1
1	Completed	Treatment	Myelodysplastic Syndromes	1
1	Completed	Treatment	Myelodysplastic Syndromes (MDS)	1
1	Completed	Treatment	Neoplasms	1
1	Completed	Treatment	Plasma Cell Myeloma	2
1	Completed	Treatment	Prostate Cancer	1
1	Completed	Treatment	Refractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1	Completed	Treatment	Relapsed Multiple Myeloma	1
1	Completed	Treatment	Relapsed Or Refractory Multiple Myeloma	1
1	Completed	Treatment	Smoldering Multiple Myeloma (SMM)	1
1	Completed	Treatment	Tumors, Solid	1
1	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	2
1	Not Yet Recruiting	Treatment	Burkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)	1
1	Not Yet Recruiting	Treatment	CLL / Richter's Syndrome	1
1	Not Yet Recruiting	Treatment	Hypercalcemia / Plasmacytoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1	Not Yet Recruiting	Treatment	Neuroblastomas	1
1	Recruiting	Prevention	Smoldering Multiple Myeloma (SMM)	1
1	Recruiting	Treatment	Acute Myeloid Leukaemias (AML)	1
1	Recruiting	Treatment	Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome	2
1	Recruiting	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia	1
1	Recruiting	Treatment	Autoimmune Pancreatitis / IgG4-related Disease / IgG4-related Sclerosing Cholangitis / Immunoglobulin G Subclass 4 Related Disease / Retroperitoneal Fibrosis	1
1	Recruiting	Treatment	B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma	1
1	Recruiting	Treatment	B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / CD19 Positive / Mediastinal Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma	1
1	Recruiting	Treatment	B-Cell Prolymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma	1
1	Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	1
1	Recruiting	Treatment	Follicular Lymphoma (FL)	1
1	Recruiting	Treatment	Follicular Lymphoma (FL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / Primary Mediastinal B-Cell Lymphoma	1
1	Recruiting	Treatment	Haematological Malignancies / Plasma Cell Myeloma	1
1	Recruiting	Treatment	Intraocular Lymphoma / Recurrent/Refractory CNS	1
1	Recruiting	Treatment	Leukemias	1
1	Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1	Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
1	Recruiting	Treatment	Multiple Myeloma (MM)	8
1	Recruiting	Treatment	Myelodysplastic Syndromes / Myeloid Leukemias	1
1	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
1	Recruiting	Treatment	Partial Response of Multiple Myeloma or Plasma Cell Leukemia / Plasma Cell Myeloma	1
1	Recruiting	Treatment	Recurrent Neuroblastoma / Stage 4 Neuroblastoma	1
1	Recruiting	Treatment	Tumors, Central Nervous System	1
1	Recruiting	Treatment	Tumors, Solid	1
1	Terminated	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes	1
1	Terminated	Treatment	Acute Myeloid Leukaemias (AML)	1
1	Terminated	Treatment	Adult Grade III Lymphomatoid Granulomatosis / Adult Non-Hodgkin's Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1	Terminated	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1	Terminated	Treatment	Advanced Cancers	1
1	Terminated	Treatment	B-Cell Chronic Lymphocytic Leukemia	1
1	Terminated	Treatment	Cancer, Ovarian / Fallopian Tube Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma	1
1	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Lymphocytic, Chronic, B-Cell / Small Lymphocytic Lymphoma (SLL)	1
1	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Small Lymphocytic	1
1	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	1
1	Terminated	Treatment	Hepatocellular,Carcinoma	1
1	Terminated	Treatment	Malignant Gliomas	1
1	Terminated	Treatment	Malignant Lymphomas / Multiple Myeloma (MM)	1
1	Terminated	Treatment	Malignant Neoplasm of Colon / Rectal Carcinoma	1
1	Terminated	Treatment	Multiple Myeloma (MM)	1
1	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Terminated	Treatment	Plasma Cell Myeloma	1
1	Terminated	Treatment	Prostate Cancer	1
1	Terminated	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1	Unknown Status	Treatment	Advanced Solid Tumors	1
1, 2	Active Not Recruiting	Treatment	AIDS-Related Hodgkin Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome	1
1, 2	Active Not Recruiting	Treatment	Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	Chronic Myelomonocytic Leukemia	1
1, 2	Active Not Recruiting	Treatment	Diffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed	1
1, 2	Active Not Recruiting	Treatment	Indolent Plasma Cell Myeloma / Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma	1
1, 2	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1, 2	Active Not Recruiting	Treatment	Malignant Lymphomas	2
1, 2	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	10
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
1, 2	Active Not Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
1, 2	Active Not Recruiting	Treatment	Plasma Cell Myeloma	1
1, 2	Active Not Recruiting	Treatment	Recurrent Adult Hodgkin's Lymphoma	1
1, 2	Active Not Recruiting	Treatment	Recurrent Thyroid Gland Carcinoma / Stage I Thyroid Gland Follicular Carcinoma / Stage I Thyroid Gland Papillary Carcinoma / Stage II Thyroid Gland Follicular Carcinoma / Stage II Thyroid Gland Papillary Carcinoma / Stage III Thyroid Gland Follicular Carcinoma / Stage III Thyroid Gland Papillary Carcinoma / Stage IV Thyroid Gland Follicular Carcinoma / Stage IV Thyroid Gland Papillary Carcinoma / Stage IVA Thyroid Gland Follicular Carcinoma / Stage IVA Thyroid Gland Papillary Carcinoma / Stage IVB Thyroid Gland Follicular Carcinoma / Stage IVB Thyroid Gland Papillary Carcinoma / Stage IVC Thyroid Gland Follicular Carcinoma / Stage IVC Thyroid Gland Papillary Carcinoma	1
1, 2	Active Not Recruiting	Treatment	Refractory Multiple Myeloma	2
1, 2	Active Not Recruiting	Treatment	Refractory Multiple Myeloma / Smoldering Multiple Myeloma (SMM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1, 2	Active Not Recruiting	Treatment	Relapsed or Refractory / Relapsed or Refractory B- / T-Cell Lymphomas	1
1, 2	Active Not Recruiting	Treatment	Relapsed/Refractory Mantle Cell Lymphoma	1
1, 2	Completed	Not Available	Cancer, Ovarian	1
1, 2	Completed	Not Available	Chronic Lymphocytic Leukaemia (CLL)	1
1, 2	Completed	Treatment	Acute Myeloid Leukaemias (AML) / Adult Acute Myeloblastic Leukemia	1
1, 2	Completed	Treatment	Amyloidosis	1
1, 2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / CLL	1
1, 2	Completed	Treatment	Cancer Cachexia Syndrome	1
1, 2	Completed	Treatment	Carcinoma, Pancreatic	1
1, 2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL)	4
1, 2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Completed	Treatment	Kaposi's Sarcoma AIDS Related / Recurrent Kaposi's Sarcoma	1
1, 2	Completed	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell	1
1, 2	Completed	Treatment	Leukemia, Myeloid, Acute	1
1, 2	Completed	Treatment	Leukemias	1
1, 2	Completed	Treatment	Leukemias / Myelodysplastic Syndromes	1
1, 2	Completed	Treatment	Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)	1
1, 2	Completed	Treatment	Malignancies, Hematologic / Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Malignant Lymphomas	2
1, 2	Completed	Treatment	Mantle Cell Lymphoma (MCL)	1
1, 2	Completed	Treatment	Multiple Myeloma (MM)	7
1, 2	Completed	Treatment	Plasma Cell Myeloma	1
1, 2	Completed	Treatment	Plasma Cell Myeloma / Transplantation, Stem Cell	1
1, 2	Completed	Treatment	Prostate Cancer	2
1, 2	Completed	Treatment	Recurrent Ovarian Cancer	1
1, 2	Completed	Treatment	Refractory Multiple Myeloma / Relapses	1
1, 2	Completed	Treatment	Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Not Yet Recruiting	Treatment	Lymphoma, B Cell / Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia	1
1, 2	Recruiting	Treatment	Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma	1
1, 2	Recruiting	Treatment	CD20 Positive / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma	1
1, 2	Recruiting	Treatment	Cancer, Advanced	1
1, 2	Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma	1
1, 2	Recruiting	Treatment	Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) / Follicular Lymphoma Patients (Phase IB)	1
1, 2	Recruiting	Treatment	Folliculotropic Mycosis Fungoides / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mycosis Fungoides / Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified / Sezary Syndrome	1
1, 2	Recruiting	Treatment	Grade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Waldenstrom Macroglobulinemia / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma	1
1, 2	Recruiting	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell / Malignant Lymphomas	1
1, 2	Recruiting	Treatment	Lymphoma, B-Cell	1
1, 2	Recruiting	Treatment	Lymphoma, B-Cell / Primary Effusion Lymphomas	1
1, 2	Recruiting	Treatment	Malignant Lymphomas	4
1, 2	Recruiting	Treatment	Multiple Myeloma (MM)	6
1, 2	Recruiting	Treatment	Nonsmall Cell Lung Cancer / Relapsed or Refractory Solid Tumors	1
1, 2	Recruiting	Treatment	Plasma Cell Leukemia in Remission / Plasma Cell Myeloma	1
1, 2	Recruiting	Treatment	Plasma Cell Myeloma	1
1, 2	Recruiting	Treatment	Recurrent Chronic Lymphocytic Leukemia	1
1, 2	Recruiting	Treatment	Recurrent Plasma Cell Myeloma	1
1, 2	Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1, 2	Recruiting	Treatment	Refractory Diffuse Large B-Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma	1
1, 2	Recruiting	Treatment	Relapsed Hodgkin Lymphoma / Relapsed Non-Hodgkin's Lymphoma	1
1, 2	Recruiting	Treatment	Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma	1
1, 2	Terminated	Treatment	Aggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant	1
1, 2	Terminated	Treatment	Cancer, Ovarian	1
1, 2	Terminated	Treatment	Cancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer	1
1, 2	Terminated	Treatment	Low to Intermediate-1 MDS / Myelodysplastic Syndrome / Non-deletion 5q / Smith-Magenis Syndrome	1
1, 2	Terminated	Treatment	Lymphoma, Hodgkins / Mature T-cell Lymphoma / Multiple Myeloma (MM)	1
1, 2	Terminated	Treatment	Malignant Neoplasm of Pancreas	1
1, 2	Terminated	Treatment	Multiple Myeloma (MM)	1
1, 2	Terminated	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
1, 2	Terminated	Treatment	Peripheral T-Cell Non-Hodgkin's Lymphoma	1
1, 2	Terminated	Treatment	Relapsed Or Refractory Multiple Myeloma	1
1, 2	Terminated	Treatment	Renal Cell Adenocarcinoma	1
1, 2	Terminated	Treatment	Urinary Bladder Neoplasms	1
1, 2	Unknown Status	Treatment	Adenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer	1
1, 2	Unknown Status	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Unknown Status	Treatment	Amyloidosis	1
1, 2	Unknown Status	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	1
1, 2	Unknown Status	Treatment	Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma	1
1, 2	Unknown Status	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1, 2	Unknown Status	Treatment	Multiple Myeloma (MM)	4
1, 2	Unknown Status	Treatment	Tumors, Solid	1
1, 2	Withdrawn	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
1, 2	Withdrawn	Treatment	Follicular Lymphoma (FL) / Malignant Lymphomas	1
1, 2	Withdrawn	Treatment	Multiple Myeloma (MM)	2
2	Active Not Recruiting	Treatment	Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukaemias (AML)	1
2	Active Not Recruiting	Treatment	Acute Myeloid Leukaemias (AML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome	1
2	Active Not Recruiting	Treatment	Adult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma	1
2	Active Not Recruiting	Treatment	Adult Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Chronic Myelomonocytic Leukemia-1 / Chronic Myelomonocytic Leukemia-2 / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts	1
2	Active Not Recruiting	Treatment	Adult T-cell lymphomas/leukaemias	1
2	Active Not Recruiting	Treatment	Advanced Myeloma / Plasma Cell Myeloma	1
2	Active Not Recruiting	Treatment	Agnogenic Myeloid Metaplasia	1
2	Active Not Recruiting	Treatment	Bladder Cancers	1
2	Active Not Recruiting	Treatment	CD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / CLL	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL)	2
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	3
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma	1
2	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Active Not Recruiting	Treatment	Follicular Lymphoma (FL) / Lymphoma of Mucosa-Associated Lymphoid Tissue / Lymphoma, Mantle-Cell / MALT Lymphoma / Marginal Zone B-Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)	1
2	Active Not Recruiting	Treatment	Lenalidomide / Malignant Lymphomas / Relapses / Rituximab	1
2	Active Not Recruiting	Treatment	Leukemias / Malignant Lymphomas	2
2	Active Not Recruiting	Treatment	Lymphoma, Mantle-Cell / Mantle Cell Lymphoma (MCL)	1
2	Active Not Recruiting	Treatment	Malignant Lymphomas	4
2	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	3
2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	22
2	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Renal Failure	1
2	Active Not Recruiting	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
2	Active Not Recruiting	Treatment	Myelodysplastic Syndrome	3
2	Active Not Recruiting	Treatment	Myelodysplastic Syndromes	2
2	Active Not Recruiting	Treatment	Myelodysplastic Syndrome / Smith-Magenis Syndrome	1
2	Active Not Recruiting	Treatment	Myeloproliferative Diseases	1
2	Active Not Recruiting	Treatment	Neoplasms, Thyroid	1
2	Active Not Recruiting	Treatment	Neurofibromatosis Type 1 / Recurrent Childhood Pilocytic Astrocytoma / Recurrent Childhood Visual Pathway Glioma	1
2	Active Not Recruiting	Treatment	Newly Diagnosed Multiple Myeloma	1
2	Active Not Recruiting	Treatment	Non Hodgkin Lymphoma (NHL)	1
2	Active Not Recruiting	Treatment	Plasma Cell Myeloma	2
2	Active Not Recruiting	Treatment	Prostate Cancer	1
2	Active Not Recruiting	Treatment	Recurrent Mantle Cell Lymphoma	1
2	Active Not Recruiting	Treatment	Relapsed or Refractory Chronic Lymphocytic Leukemia	1
2	Active Not Recruiting	Treatment	Smoldering Multiple Myeloma (SMM) / Smoldering Myeloma	1
2	Active Not Recruiting	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	2
2	Active Not Recruiting	Treatment	Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma	1
2	Completed	Not Available	Impaired Renal Function / Multiple Myeloma (MM)	1
2	Completed	Not Available	Plasma Cell Dyscrasia	1
2	Completed	Treatment	AML / Smith-Magenis Syndrome	1
2	Completed	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome	1
2	Completed	Treatment	Acute Myeloid Leukaemias (AML)	3
2	Completed	Treatment	Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia	1
2	Completed	Treatment	Adult T Cell Leukemia/Lymphoma	1
2	Completed	Treatment	Agnogenic Myeloid Metaplasia	1
2	Completed	Treatment	Amyloidosis	2
2	Completed	Treatment	Angiogenesis / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes	1
2	Completed	Treatment	Autism, Early Infantile	1
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / CLL / Leukemias / Small Lymphocytic Lymphoma (SLL)	1
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL)	5
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Leukemias	2
2	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)	3
2	Completed	Treatment	Complex Regional Pain Syndrome (RSD)	1
2	Completed	Treatment	Crohn's Disease (CD)	1
2	Completed	Treatment	Essential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis	1
2	Completed	Treatment	Follicular Lymphoma (FL)	1
2	Completed	Treatment	Glioblastomas / Gliosarcoma / Malignant Gliomas	1
2	Completed	Treatment	Hematologic Cancers	1
2	Completed	Treatment	Hodgkins Disease (HD)	2
2	Completed	Treatment	Leukemia, Lymphocytic / Mantle Cell Lymphoma (MCL)	1
2	Completed	Treatment	Leukemia, Myeloid, Acute	1
2	Completed	Treatment	Leukemias	1
2	Completed	Treatment	Liver Cancer	2
2	Completed	Treatment	Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)	1
2	Completed	Treatment	Malignant Lymphomas	3
2	Completed	Treatment	Mantle Cell Lymphoma (MCL)	1
2	Completed	Treatment	Melanoma	1
2	Completed	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
2	Completed	Treatment	Multiple Myeloma (MM)	24
2	Completed	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	4
2	Completed	Treatment	Myelodysplastic Syndrome	2
2	Completed	Treatment	Myelodysplastic Syndromes	6
2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	3
2	Completed	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	POEMS Syndrome	2
2	Completed	Treatment	Pancreatic Cancer Metastatic	1
2	Completed	Treatment	Primary Plasma Cell Leukemia	1
2	Completed	Treatment	Primary Systemic Amyloidosis	1
2	Completed	Treatment	Prostate Cancer	1
2	Completed	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Completed	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Completed	Treatment	Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)	1
2	Completed	Treatment	Renal Cancers	2
2	Completed	Treatment	Squamous Cell Carcinoma (SCC)	1
2	Completed	Treatment	T-Cell Lymphomas	1
2	Completed	Treatment	Light chain amyloidosis	1
2	Not Yet Recruiting	Treatment	AML	1
2	Not Yet Recruiting	Treatment	B-cell Non-Hodgkin's Lymphomas	1
2	Not Yet Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
2	Not Yet Recruiting	Treatment	EBV Related Non-Hodgkin's Lymphoma / Primary CNS Lymphoma / Primary Testicular Lymphoma	1
2	Not Yet Recruiting	Treatment	Hematopoietic/Lymphoid Cancer / Mantle Cell Lymphoma (MCL)	1
2	Not Yet Recruiting	Treatment	Mucosa Associated Lymphoid Tissue (MALT) Lymphoma	1
2	Not Yet Recruiting	Treatment	Multiple Myeloma (MM)	4
2	Not Yet Recruiting	Treatment	Plasma Cell Myeloma	1
2	Recruiting	Supportive Care	Multiple Myeloma (MM)	1
2	Recruiting	Treatment	Adult Myelodysplastic Syndrome / Anemias / Chronic Myelomonocytic Leukemia	1
2	Recruiting	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome	1
2	Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL)	2
2	Recruiting	Treatment	Contiguous Stage II Small Lymphocytic Lymphoma / Leukemia, Prolymphocytic / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma	1
2	Recruiting	Treatment	Follicular Lymphoma (FL)	1
2	Recruiting	Treatment	Follicular Lymphoma (FL) / Malignant Lymphomas	1
2	Recruiting	Treatment	Histiocytic Sarcoma (HS) / Histiocytoses Erdheim-chester Disease / Langerhans Cell Histiocytosis (LCH)	1
2	Recruiting	Treatment	Leukemia, Myeloid, Acute / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes	1
2	Recruiting	Treatment	Leukemias	2
2	Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	2
2	Recruiting	Treatment	Malignant Lymphomas	1
2	Recruiting	Treatment	Malignant Lymphomas / Neurotoxicity / Therapy-Related Toxicity	1
2	Recruiting	Treatment	Mantle Cell Lymphoma (MCL) / Untreated	1
2	Recruiting	Treatment	Monoclonal B-Cell Lymphocytosis / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma	1
2	Recruiting	Treatment	Multiple Myeloma (MM)	13
2	Recruiting	Treatment	Myelodysplastic Syndromes	1
2	Recruiting	Treatment	Myeloid Leukemias	1
2	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Recruiting	Treatment	POEMS Syndrome	1
2	Recruiting	Treatment	Plasmacytoma / POEMS Syndrome	1
2	Recruiting	Treatment	Plasma Cell Myeloma	2
2	Recruiting	Treatment	Plasma Cell Myeloma / Residual Disease	1
2	Recruiting	Treatment	Plasma Cell Myeloma / Transplant-Related Carcinoma	1
2	Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Multiple Myeloma / Refractory Plasma Cell Myeloma	1
2	Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Recruiting	Treatment	Relapse/Refractory Multiple Myeloma	1
2	Recruiting	Treatment	Relapsed/Refractory Mantle Cell Lymphoma	1
2	Recruiting	Treatment	Smith-Magenis Syndrome	1
2	Recruiting	Treatment	Smoldering Multiple Myeloma (SMM)	2
2	Recruiting	Treatment	Smoldering Multiple Myeloma (SMM) / Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma	1
2	Recruiting	Treatment	T-Cell Lymphomas	1
2	Suspended	Supportive Care	Neuropathy / Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)	1
2	Terminated	Other	Haematological disorders	1
2	Terminated	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes	1
2	Terminated	Treatment	Acute Myeloid Leukaemias (AML) / Leukemias / Myelodysplastic Syndromes (MDS)	1
2	Terminated	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)	1
2	Terminated	Treatment	Cancer, Advanced / Pain	1
2	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL)	4
2	Terminated	Treatment	Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)	1
2	Terminated	Treatment	Colorectal Cancers	1
2	Terminated	Treatment	Complex Regional Pain Syndrome, Type I	1
2	Terminated	Treatment	Follicular Lymphoma (FL) / Marginal Zone Lymphoma	1
2	Terminated	Treatment	Graft Versus Host Disease (GVHD)	1
2	Terminated	Treatment	HIV Infection Associated Kaposi Disease	1
2	Terminated	Treatment	Intraocular Melanoma / Malignant Conjunctival Neoplasm	1
2	Terminated	Treatment	Leukemias	1
2	Terminated	Treatment	Leukemias / Relapsed Adult Acute Lymphocytic Leukemia	1
2	Terminated	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2	Terminated	Treatment	Multiple Myeloma (MM)	3
2	Terminated	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
2	Terminated	Treatment	Myelodysplastic Syndrome MDS	1
2	Terminated	Treatment	Peripheral T-Cell Lymphoma (PTCL)	1
2	Terminated	Treatment	Refractory Plasma Cell Myeloma	1
2	Terminated	Treatment	Smith-Magenis Syndrome	1
2	Terminated	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Terminated	Treatment	T-Cell Non-Hodgkin Lymphoma	1
2	Terminated	Treatment	Waldenstrom's Macroglobulinemia (WM)	2
2	Unknown Status	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome	1
2	Unknown Status	Treatment	Chronic Lymphocytic Leukaemia (CLL) / CLL / First-Line / Front-line / Initial Therapy / Untreated	1
2	Unknown Status	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia	1
2	Unknown Status	Treatment	Cutaneous T Cell Lymphomas (CTCL)	1
2	Unknown Status	Treatment	Indolent Non Hodgkin Lymphoma	1
2	Unknown Status	Treatment	Leukemia, Lymphocytic / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	1
2	Unknown Status	Treatment	Leukemias	1
2	Unknown Status	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	2
2	Unknown Status	Treatment	MALT Lymphoma	1
2	Unknown Status	Treatment	Malignant Lymphomas	2
2	Unknown Status	Treatment	Multiple Myeloma (MM)	3
2	Unknown Status	Treatment	Myelodysplastic Syndrome	1
2	Unknown Status	Treatment	Myelodysplastic Syndromes	1
2	Unknown Status	Treatment	POEMS Syndrome	1
2	Unknown Status	Treatment	Refractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Withdrawn	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
2	Withdrawn	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia	1
2	Withdrawn	Treatment	Leukemias / Malignant Lymphomas	1
2	Withdrawn	Treatment	Malignant Gliomas	1
2	Withdrawn	Treatment	Multiple Myeloma (MM)	3
2	Withdrawn	Treatment	Multiple Myeloma (MM) / Plasma Cell Myeloma	1
2, 3	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2, 3	Completed	Treatment	Radicular syndrome	1
2, 3	Recruiting	Treatment	Multiple Myeloma (MM)	2
3	Active Not Recruiting	Basic Science	Newly Diagnosed, Previously Untreated Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Anemias	1
3	Active Not Recruiting	Treatment	Anemias / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes	1
3	Active Not Recruiting	Treatment	B-Cell Chronic Lymphocytic Leukemia	1
3	Active Not Recruiting	Treatment	B-Cell Chronic Lymphocytic Leukemia (B-CLL)	1
3	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma	1
3	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma	1
3	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Follicular Lymphoma (FL)	2
3	Active Not Recruiting	Treatment	Light Chain Deposition Disease / Smoldering Plasma Cell Myeloma	1
3	Active Not Recruiting	Treatment	Lymphoma (Myeloma) / Multiple Myeloma (MM)	1
3	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
3	Active Not Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas	1
3	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
3	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	9
3	Active Not Recruiting	Treatment	Multiple Myeloma (MM) / Newly Diagnosed Patients	1
3	Active Not Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
3	Active Not Recruiting	Treatment	Plasma Cell Myeloma	2
3	Active Not Recruiting	Treatment	Previously Untreated Symptomatic Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Relapsed Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Completed	Diagnostic	Multiple Myeloma (MM)	1
3	Completed	Prevention	Melanoma / Neoplasms Metastasis	1
3	Completed	Treatment	Multiple Myeloma (MM)	10
3	Completed	Treatment	Multiple Myeloma (MM) / Plasma Cell Neoplasms	1
3	Completed	Treatment	Myelodysplastic Syndromes	1
3	Completed	Treatment	Newly Diagnosed Multiple Myeloma	1
3	Completed	Treatment	Prostate Cancer	1
3	Completed	Treatment	Relapsed Or Refractory Multiple Myeloma	1
3	Not Yet Recruiting	Treatment	Plasmacytoma	1
3	Recruiting	Treatment	Follicular Lymphoma (FL)	1
3	Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
3	Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
3	Recruiting	Treatment	Multiple Myeloma (MM)	10
3	Recruiting	Treatment	Myelodysplastic Syndrome	1
3	Recruiting	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
3	Recruiting	Treatment	Relapsed or Refractory Systemic Light Chain Amyloidosis	1
3	Recruiting	Treatment	Solitary Osseous Plasmacytoma	1
3	Recruiting	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Suspended	Treatment	Multiple Myeloma (MM)	1
3	Terminated	Treatment	Chronic Lymphocytic Leukaemia (CLL)	1
3	Terminated	Treatment	Malignant Lymphomas	1
3	Terminated	Treatment	Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)	1
3	Terminated	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Withdrawn	Treatment	Blood Protein Disorders / Hematologic Diseases / Multiple Myeloma (MM) / Neoplasms / Paraproteinemias / Plasma Cells / Therapeutic Uses	1
4	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	2
4	Completed	Treatment	Cutaneous Lupus	1
4	Not Yet Recruiting	Treatment	Multiple Myeloma (MM)	1
4	Terminated	Treatment	AML	1
Not Available	Active Not Recruiting	Not Available	Multiple Myeloma (MM)	1
Not Available	Active Not Recruiting	Treatment	CLL / Leukemias	1
Not Available	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
Not Available	Available	Not Available	Multiple Myeloma (MM)	1
Not Available	Available	Not Available	Multiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
Not Available	Completed	Not Available	Multiple Myeloma (MM)	1
Not Available	Completed	Not Available	Myelodysplastic Syndrome	1
Not Available	Completed	Treatment	Acute Myeloid Leukaemias (AML) / Anemias / Dysmyelopoietic Syndromes / Leukemia, Myelocytic, Acute / Leukemias / Myelodysplastic Syndromes (MDS)	1
Not Available	Completed	Treatment	Amyloidosis / Leukemias	1
Not Available	Completed	Treatment	Cutaneous Lupus Erythematosus (CLE)	1
Not Available	Completed	Treatment	Multiple Myeloma (MM)	1
Not Available	Recruiting	Not Available	Malignant Lymphomas	1
Not Available	Recruiting	Not Available	Multiple Myeloma (MM)	2
Not Available	Recruiting	Not Available	Myelodysplastic Syndrome / Myelodysplastic Syndromes (MDS)	1
Not Available	Recruiting	Treatment	Blood And Marrow Transplantation / Leukemias / Malignant Lymphomas	1
Not Available	Terminated	Not Available	Multiple Myeloma (MM)	1
Not Available	Terminated	Treatment	B-Cell Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia	1
Not Available	Terminated	Treatment	Plasma Cell Myeloma	1

Pharmacoeconomics

Manufacturers

Celgene corp
Celgene Corporation

Packagers

Dosage forms

Form	Route	Strength
Capsule	Oral	10 mg/1
Capsule	Oral	10 mg
Capsule	Oral	15 mg/1
Capsule	Oral	15 mg
Capsule	Oral	2.5 mg/1
Capsule	Oral	2.5 mg
Capsule	Oral	20 mg/1
Capsule	Oral	20 mg
Capsule	Oral	25 mg
Capsule	Oral	25 mg/1
Capsule	Oral	5 mg
Capsule	Oral	5 mg/1
Capsule	Oral	7.5 mg

Prices

Unit description	Cost	Unit
Revlimid 25 mg capsule	411.71USD	capsule
Revlimid 15 mg capsule	407.7USD	capsule
Revlimid 10 mg capsule	406.05USD	capsule
Revlimid 5 mg capsule	388.0USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2477301	No	2009-09-01	2023-04-13	Canada
CA2342974	No	2005-08-16	2014-02-24	Canada
US6045501	No	1998-08-28	2018-08-28	US
US6315720	No	2000-10-23	2020-10-23	US
US6561976	No	1998-08-28	2018-08-28	US
US6561977	No	2000-10-23	2020-10-23	US
US6755784	No	2000-10-23	2020-10-23	US
US6908432	No	1998-08-28	2018-08-28	US
US8204763	No	1998-08-28	2018-08-28	US
US8315886	No	2000-10-23	2020-10-23	US
US8626531	No	2000-10-23	2020-10-23	US
US8589188	No	1998-08-28	2018-08-28	US
US7468363	No	2003-10-07	2023-10-07	US
US6281230	No	1996-07-24	2016-07-24	US
US8530498	No	2003-05-15	2023-05-15	US
US6555554	No	1996-07-24	2016-07-24	US
US7189740	No	2003-04-11	2023-04-11	US
US7968569	No	2003-10-07	2023-10-07	US
US8404717	No	2003-04-11	2023-04-11	US
US8648095	No	2003-05-15	2023-05-15	US
US8741929	No	2008-03-08	2028-03-08	US
US9101622	No	2003-05-15	2023-05-15	US
US9101621	No	2003-05-15	2023-05-15	US
US9056120	No	2003-04-11	2023-04-11	US
US5635517	No	1999-10-04	2019-10-04	US
US7119106	No	1996-07-24	2016-07-24	US
US7465800	No	2007-04-27	2027-04-27	US
US7855217	No	2004-11-24	2024-11-24	US
US8288415	No	1996-07-24	2016-07-24	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.	Not Available
logP	-0.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	2.33 mg/mL	ALOGPS
logP	-0.43	ALOGPS
logP	-0.71	ChemAxon
logS	-2	ALOGPS
pKa (Strongest Acidic)	11.61	ChemAxon
pKa (Strongest Basic)	2.31	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	92.5 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	68.3 m³·mol^-1	ChemAxon
Polarizability	25.55 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9958
Blood Brain Barrier	+	0.9372
Caco-2 permeable	-	0.5981
P-glycoprotein substrate	Substrate	0.6845
P-glycoprotein inhibitor I	Inhibitor	0.6012
P-glycoprotein inhibitor II	Non-inhibitor	0.8927
Renal organic cation transporter	Non-inhibitor	0.726
CYP450 2C9 substrate	Non-substrate	0.8861
CYP450 2D6 substrate	Non-substrate	0.7878
CYP450 3A4 substrate	Substrate	0.5855
CYP450 1A2 substrate	Non-inhibitor	0.8746
CYP450 2C9 inhibitor	Non-inhibitor	0.8405
CYP450 2D6 inhibitor	Non-inhibitor	0.8806
CYP450 2C19 inhibitor	Non-inhibitor	0.78
CYP450 3A4 inhibitor	Non-inhibitor	0.7469
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.843
Ames test	Non AMES toxic	0.8268
Carcinogenicity	Non-carcinogens	0.9068
Biodegradation	Not ready biodegradable	0.9967
Rat acute toxicity	2.5145 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9803
hERG inhibition (predictor II)	Non-inhibitor	0.5098

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-0002-1920000000-c10c48acd9b8123e3505	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-qTof , Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Isoindoles and derivatives

Sub Class

Isoindolines

Direct Parent

Isoindolones

Alternative Parents

Alpha amino acids and derivatives / Isoindoles / Piperidinediones / Delta lactams / Benzenoids / Tertiary carboxylic acid amides / N-unsubstituted carboxylic acid imides / Dicarboximides / Azacyclic compounds / Primary amines

Substituents

Alpha-amino acid or derivatives / Isoindolone / Isoindole / Piperidinedione / Delta-lactam / Piperidinone / Piperidine / Benzenoid / Carboxylic acid imide / Dicarboximide

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

dicarboximide, aromatic amine, piperidones, isoindoles (CHEBI:63791 )

Targets

Details

1. Protein cereblon

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Metal ion binding
Specific Function:: Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly an...
Gene Name:: CRBN
Uniprot ID:: Q96SW2
Uniprot Name:: Protein cereblon
Molecular Weight:: 50545.375 Da

References

Zhu YX, Kortuem KM, Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. [PubMed:22966948 ]

Details

2. Tumor necrosis factor ligand superfamily member 11

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Tumor necrosis factor receptor superfamily binding
Specific Function:: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced b...
Gene Name:: TNFSF11
Uniprot ID:: O14788
Uniprot Name:: Tumor necrosis factor ligand superfamily member 11
Molecular Weight:: 35477.81 Da

References

Akobeng AK, Stokkers PC: Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. doi: 10.1002/14651858.CD007351.pub2. [PubMed:19370685 ]
Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-99. Epub 2007 Jan 30. [PubMed:17369076 ]

Details

3. Cadherin-5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Receptor binding
Specific Function:: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-cate...
Gene Name:: CDH5
Uniprot ID:: P33151
Uniprot Name:: Cadherin-5
Molecular Weight:: 87527.715 Da

References

Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4. [PubMed:18805433 ]

Details

4. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: negative modulator

General Function:: Prostaglandin-endoperoxide synthase activity
Specific Function:: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:: PTGS2
Uniprot ID:: P35354
Uniprot Name:: Prostaglandin G/H synthase 2
Molecular Weight:: 68995.625 Da

References

Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8. [PubMed:15598423 ]
Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI: Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):275-81. [PubMed:12720152 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

Drug created on June 13, 2005 07:24 / Updated on August 08, 2017 11:04

Structure for DB00480 (Lenalidomide)

Targets

References

References

References

References

Transporters